Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

FDA provides very specific guidelines to study iPSC-derived MSCs Company intends to submit an IND application for its iMSC therapy for patients with ARDS associated with COVID-19 CRANFORD, N.J., June 26, 2020 -- (Healthcare Sales & Marketing Network)... Biopharmaceuticals, FDA Citius Pharmaceuticals, Induced Mesenchymal Stem Cells, ARDS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news